<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="ACE inhibitors: heart failure; ACE inhibitors: hypertension; Antihypertensives: ACE inhibitors; Angiotensin-converting enzyme inhibitors see ACE inhibitors; Heart failure: ACE inhibitors; Hypertension: ACE inhibitors; ACE inhibitors: renal function" /><meta name="IX" content="ACE inhibitors: heart failure; ACE inhibitors: hypertension; Antihypertensives: ACE inhibitors; Heart failure: ACE inhibitors; Hypertension: ACE inhibitors; ACE inhibitors: renal function" /><meta name="IXN" content="Angiotensin-converting enzyme inhibitors see ACE inhibitors" /><title>2.5.5.1 Angiotensin-converting enzyme inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1124-angiotensin-converting-enzyme-inhibitors.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1034-hypertension-and-heart-failure.htm">2.5 Hypertension and heart failure</a> &gt; <a href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">2.5.5 Drugs affecting the renin-angiotensin system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1123-heart-failure.htm" title="Previous: Heart failure">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1138-captopril.htm" title="Next: CAPTOPRIL">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>2.5.5.1 </span>Angiotensin-converting enzyme inhibitors</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a>).</p></div></div><p>Angiotensin-converting enzyme inhibitors (ACE inhibitors) inhibit the conversion of angiotensin I to angiotensin II. They have many uses and are generally well tolerated. The main indications of ACE inhibitors are shown below.</p><div id="PHP1125"><h2>Heart failure</h2><p>ACE inhibitors are used in all grades of heart failure, usually combined with a beta-blocker (<a title=" Drugs affecting the renin-angiotensin system" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">section 2.5.5</a>). Potassium supplements and potassium-sparing diuretics should be discontinued before introducing an ACE inhibitor because of the risk of hyperkalaemia. However, a low dose of spironolactone may be beneficial in severe heart failure (<a title=" Drugs affecting the renin-angiotensin system" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">section 2.5.5</a>) and can be used with an ACE inhibitor provided serum potassium is monitored carefully. Profound first-dose hypotension may occur when ACE inhibitors are introduced to patients with heart failure who are already taking a high dose of a loop diuretic (e.g. furosemide 80 mg daily or more). Temporary withdrawal of the loop diuretic reduces the risk, but may cause severe rebound pulmonary oedema. Therefore, for patients on high doses of loop diuretics, the ACE inhibitor may need to be initiated under specialist supervision, see below. An ACE inhibitor can be initiated in the community in patients who are receiving a low dose of a diuretic or who are not otherwise at risk of serious hypotension; nevertheless, care is required and a very low dose of the ACE inhibitor is given initially.</p></div><div id="PHP1126"><h2>Hypertension</h2><p>An ACE inhibitor may be the most appropriate initial drug for hypertension in younger Caucasian patients; Afro-Caribbean patients, those aged over 55 years, and those with primary aldosteronism respond less well (see <a title="section: Hypertension and heart failure" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>). ACE inhibitors are particularly indicated for hypertension in patients with type 1 diabetes with nephropathy (see also <a title=" Treatment of diabetic nephropathy and neuropathy" href="PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy.htm">section 6.1.5</a>). They may reduce blood pressure very rapidly in some patients particularly in those receiving diuretic therapy (see Cautions, below); the first dose should preferably be given at bedtime.</p></div><div><h2>Diabetic nephropathy</h2><p>For comment on the role of ACE inhibitors in the management of diabetic nephropathy, see <a title=" Treatment of diabetic nephropathy and neuropathy" href="PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy.htm">section 6.1.5</a>.</p></div><div><h2>Prophylaxis of cardiovascular events</h2><p>ACE inhibitors are used in the early and long-term management of patients who have had a myocardial infarction, see <a title=" Management of myocardial infarction" href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">section 2.10.1</a>. ACE inhibitors may also have a role in preventing cardiovascular events.</p></div><div id="PHP1127"><h2>Initiation under specialist supervision</h2><p>ACE inhibitors should be initiated under specialist supervision and with careful clinical monitoring in those with severe heart failure or in those: </p><ul><li><p>receiving multiple or high-dose diuretic therapy (e.g. more than 80 mg of furosemide daily or its equivalent);</p> </li><li><p>with hypovolaemia;</p> </li><li><p>with hyponatraemia (plasma-sodium concentration below 130 mmol/litre);</p> </li><li><p>with hypotension (systolic blood pressure below 90 mmHg);</p> </li><li><p>with unstable heart failure;</p> </li><li><p>receiving high-dose vasodilator therapy;</p> </li><li><p>known renovascular disease.</p> </li></ul></div><div id="PHP1128"><h2>Renal effects</h2><p>Renal function and electrolytes should be checked before starting ACE inhibitors (or increasing the dose) and monitored during treatment (more frequently if features mentioned below present); hyperkalaemia and other side-effects of ACE inhibitors are more common in those with impaired renal function and the dose may need to be reduced (see Renal impairment below and under individual drugs). Although ACE inhibitors now have a specialised role in some forms of renal disease, including chronic kidney disease, they also occasionally cause impairment of renal function which may progress and become severe in other circumstances (at particular risk are the elderly). A specialist should be involved if renal function is significantly reduced as a result of treatment with an ACE inhibitor.</p><p>Concomitant treatment with NSAIDs increases the risk of renal damage, and potassium-sparing diuretics (or potassium-containing salt substitutes) increase the risk of hyperkalaemia.</p><p>In patients with severe bilateral renal artery stenosis (or severe stenosis of the artery supplying a single functioning kidney), ACE inhibitors reduce or abolish glomerular filtration and are likely to cause severe and progressive renal failure. They are therefore not recommended in patients known to have these forms of critical renovascular disease.</p><p>ACE inhibitor treatment is unlikely to have an adverse effect on overall renal function in patients with severe unilateral renal artery stenosis and a normal contralateral kidney, but glomerular filtration is likely to be reduced (or even abolished) in the affected kidney and the long-term consequences are unknown. </p><p>ACE inhibitors are therefore best avoided in patients with known or suspected renovascular disease, unless the blood pressure cannot be controlled by other drugs. If ACE inhibitors are used, they should be initiated only under specialist supervision and renal function should be monitored regularly.</p><p>ACE inhibitors should also be used with particular caution in patients who may have undiagnosed and clinically silent renovascular disease. This includes patients with peripheral vascular disease or those with severe generalised atherosclerosis.</p></div><div id="PHP1129"><h2>Cautions</h2><p>ACE inhibitors need to be initiated with care in patients receiving diuretics (<strong>important:</strong> see Concomitant diuretics, below); first doses can cause hypotension especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure (see above). They should also be used with caution in peripheral vascular disease or generalised atherosclerosis owing to risk of clinically silent renovascular disease; for use in pre-existing renovascular disease, see <a title="target-block: ACE inhibitors renal effects" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#PHP1128">Renal Effects</a> above. The risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended). ACE inhibitors should be used with care in patients with severe or symptomatic aortic stenosis (risk of hypotension) and in hypertrophic cardiomyopathy. They should also be used with care (or avoided) in those with a history of idiopathic or hereditary angioedema. If jaundice or marked elevations of hepatic enzymes occur during treatment then the ACE inhibitor should be discontinued—risk of hepatic necrosis (see also Hepatic impairment, below). <strong>Interactions:</strong> Appendix 1 (ACE inhibitors).</p><div><div class="cE"><h3 class="cT">Anaphylactoid reactions</h3> <p class="cT">To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polyacrylonitrile membranes and during low-density lipoprotein apheresis with dextran sulfate; they should also be withheld before desensitisation with wasp or bee venom.</p></div></div><div><div class="cE"><h3 class="cT">Concomitant diuretics</h3> <p class="cT" id="PHP1131">ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24 hours beforehand (may not be possible in heart failure—risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.</p></div> </div></div><div id="PHP1132"><h2>Contra-indications</h2><p>ACE inhibitors are contra-indicated in patients with hypersensitivity to ACE inhibitors (including angioedema).</p></div><div id="PHP1133"><h2>Hepatic impairment</h2><p>Use of prodrugs such as cilazapril, enalapril, fosinopril, imidapril, moexipril, perindopril, quinapril, ramipril, and trandolapril requires close monitoring in patients with impaired liver function</p></div><div id="PHP1134"><h2>Renal impairment</h2><p>ACE inhibitors should be used with caution and the response monitored (see <a title="BNF:target-block: ACE inhibitors renal effects" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#PHP1128">Renal effects above</a>); hyperkalaemia and other side effects more common; the dose may need to be reduced, see individual drugs.</p></div><div id="PHP1135"><h2>Pregnancy</h2><p>ACE inhibitors should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported.</p></div><div id="PHP1136"><h2>Breast-feeding</h2><p> Information on the use of ACE inhibitors in breast-feeding is limited. Cilazapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, ramipril, and trandolapril are not recommended; alternative treatment options, with better established safety information during breast-feeding, are available. Captopril, enalapril, and quinapril should be avoided in the first few weeks after delivery, particularly in preterm infants, due to the risk of profound neonatal hypotension; if essential, they may be used in mothers breast-feeding older infants—the infant's blood pressure should be monitored.</p></div><div id="PHP1137"><h2>Side-effects</h2><p>ACE inhibitors can cause profound hypotension (see Cautions) and renal impairment (see Renal effects above), and a persistent dry cough. They can also cause angioedema (onset may be delayed; higher incidence reported in Afro-Caribbean patients), rash (which may be associated with pruritus and urticaria), pancreatitis, and upper respiratory-tract symptoms such as sinusitis, rhinitis, and sore throat. Gastro-intestinal effects reported with ACE inhibitors include nausea, vomiting, dyspepsia, diarrhoea, constipation, and abdominal pain. Altered liver function tests, cholestatic jaundice, hepatitis, fulminant hepatic necrosis, and hepatic failure have been reported—discontinue if marked elevation of hepatic enzymes or jaundice. Hyperkalaemia, hypoglycaemia, and blood disorders including thrombocytopenia, leucopenia, neutropenia, and haemolytic anaemia have also been reported. Other reported side-effects include headache, dizziness, fatigue, malaise, taste disturbance, paraesthesia, bronchospasm, fever, serositis, vasculitis, myalgia, arthralgia, positive antinuclear antibody, raised erythrocyte sedimentation rate, eosinophilia, leucocytosis, and photosensitivity.</p></div><div><h2>Combination products</h2><p>Products incorporating an ACE inhibitor with a thiazide diuretic or a calcium-channel blocker are available for the management of hypertension. Use of these combination products should be reserved for patients whose blood pressure has not responded adequately to a single antihypertensive drug and who have been stabilised on the individual components of the combination in the same proportions.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP1138-captopril"><a href="PHP1138-captopril.htm" title="CAPTOPRIL">CAPTOPRIL</a></li><li id="_PHP1145-cilazapril"><a href="PHP1145-cilazapril.htm" title="CILAZAPRIL">CILAZAPRIL</a></li><li id="_PHP1150-enalapril-maleate"><a href="PHP1150-enalapril-maleate.htm" title="ENALAPRIL MALEATE">ENALAPRIL MALEATE</a></li><li id="_PHP1157-fosinopril-sodium"><a href="PHP1157-fosinopril-sodium.htm" title="FOSINOPRIL SODIUM">FOSINOPRIL SODIUM</a></li><li id="_PHP1159-imidapril-hydrochloride"><a href="PHP1159-imidapril-hydrochloride.htm" title="IMIDAPRIL HYDROCHLORIDE">IMIDAPRIL HYDROCHLORIDE</a></li><li id="_PHP1161-lisinopril"><a href="PHP1161-lisinopril.htm" title="LISINOPRIL">LISINOPRIL</a></li><li id="_PHP1174-moexipril-hydrochloride"><a href="PHP1174-moexipril-hydrochloride.htm" title="MOEXIPRIL HYDROCHLORIDE">MOEXIPRIL HYDROCHLORIDE</a></li><li id="_PHP1176-perindopril-erbumine"><a href="PHP1176-perindopril-erbumine.htm" title="PERINDOPRIL ERBUMINE">PERINDOPRIL ERBUMINE</a></li><li id="_PHP1178-perindopril-arginine"><a href="PHP1178-perindopril-arginine.htm" title="PERINDOPRIL ARGININE">PERINDOPRIL ARGININE</a></li><li id="_PHP1184-quinapril"><a href="PHP1184-quinapril.htm" title="QUINAPRIL">QUINAPRIL</a></li><li id="_PHP1191-ramipril"><a href="PHP1191-ramipril.htm" title="RAMIPRIL">RAMIPRIL</a></li><li id="_PHP1196-ramipril-with-felodipine"><a href="PHP1196-ramipril-with-felodipine.htm" title="RAMIPRIL WITH FELODIPINE">RAMIPRIL WITH FELODIPINE</a></li><li id="_PHP1198-trandolapril"><a href="PHP1198-trandolapril.htm" title="TRANDOLAPRIL">TRANDOLAPRIL</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1123-heart-failure.htm">Previous: Heart failure</a> | <a class="top" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm#">Top</a> | <a accesskey="]" href="PHP1138-captopril.htm">Next: CAPTOPRIL</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>